Key points are not available for this paper at this time.
Our global survey reveals no cases of insertional mutagenesis following CAR T-cells in pediatric patients challenging concerns of secondary malignancy risk in this population.This underscores the safety of CAR T-cell therapy in this population, but ongoing surveillance required.
Lamble et al. (Fri,) studied this question.